Misplaced Pages

Thomas Tedder

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

Thomas Fletcher Tedder (May 14, 1956-March 18, 2024) was an American immunologist. He is best known for his work in the fields of B lymphocyte biology and regulation. He was the Alter E. Geller Professor for Research in Immunology at Duke University

Career

Tedder received his Ph.D. in molecular cell biology from the University of Alabama in 1984 and completed his postdoctoral training as a research fellow in pathology at Harvard Medical School. He was a faculty member at Dana–Farber Cancer Institute and Harvard Medical School from 1985 to 1998 before joining Duke University in 1993 as its founding chairman of immunology. Tedder studies the structure and function of B lymphocyte cell surface molecules that regulate B cell function, activation, and signal transduction. He currently has 401 total publications and 25 issued patents relating to B cells and their products, including CD19, CD20, CD22, CD83, and L-selectin. He has founded four biotherapeutic companies, including Angelica Therapeutics, Cellective Therapeutics, Cellective BioTherapy and most recently, Antigenomycs, Inc.

The drug Tedder developed at Cellective Therapeutics, inebilizumab, has now been approved for NMSOD use in the United States under the clinical name Uplizna.

References

  1. "Duke Immunology". immunology.duke.edu. Archived from the original on 2016-08-03. Retrieved 11 August 2018.
  2. "Featured LRF Researcher: Thomas F. Tedder, PhD - Lymphoma Research Foundation - Welcome". Archived from the original on 2015-09-12. Retrieved 2015-10-19.
  3. "Angelica Therapeutics: Best in Class Fusion Toxins". angelicatherapeutics.com. Retrieved 11 August 2018.
  4. "Article". www.bizjournals.com. 2015.
  5. "Accelerating Immunotherapy | Duke Department of Neurosurgery". neurosurgery.duke.edu. Retrieved 2020-07-08.
  6. "Uplizna launch is a 'testament' to NC's prowess in drug R&D | WRAL TechWire". 2020-07-01. Retrieved 2020-07-08.
Categories: